The role of osteoclastic activity in prostate cancer skeletal metastases

Drugs of Today

Volumn 38, Issue 2, 2002, Pages 91-102

  Keller, Evan T ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,10 PHENANTHROLINE; BISPHOSPHONIC ACID DERIVATIVE; COLLAGENASE 3; GELATINASE B; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE INHIBITOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; RECOMBINANT INTERLEUKIN 6; STROMELYSIN; ZOLEDRONIC ACID; CARRIER PROTEIN; MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; PEPTIDE HORMONE; PTHLH PROTEIN, HUMAN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

APOPTOSIS; BONE MATRIX; BONE METABOLISM; BONE METASTASIS; CELL ACTIVATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE RELEASE; DISEASE COURSE; HUMAN; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; ANIMAL; BONE TUMOR; MALE; METASTASIS; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR;

ANIMAL; BONE NEOPLASMS; CARRIER PROTEINS; HUMAN; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASES; MEMBRANE GLYCOPROTEINS; OSTEOCLASTS; OSTEOLYSIS; PEPTIDE HORMONES; PROSTATIC NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; ANIMALS; HUMANS; PARATHYROID HORMONE-RELATED PROTEIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B;

EID: 0036201380     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2002.38.2.820105     Document Type: Review

References (129)

1. Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo
2. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
3. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
4. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
5. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
6. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
7. Characterization of osteoclast precursors in human blood
8. Fos11 is a transcriptional target of c-Fos during osteoclast differentiation
9. The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis
10. CFU-GM-derived cells form osteoclasts at a very high efficiency
11. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: Potential implications for the pathogenesis and treatment of malignant bone diseases
12. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis
13. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
14. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
15. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
16. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and nonhematopoietic cells
17. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro
18. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40
19. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines
20. Osteoprotegerin and its cognate ligand: A new paradigm of osteoclastogenesis
21. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids
22. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues
23. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation
24. The effect of a single dose of osteoprotegerin in postmenopausal women
25. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts
26. The ratio of messenger RNA levels of receptor activator of nuclear factor kappa B ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis
27. How the osteoclast degrades bone
28. Mechanism and regulation of bone resorption by osteoclasts
29. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K
30. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization
31. Cathepsin K and the design of inhibitors of cathepsin K
32. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate
33. Osteoclasts express the B2 isoform of vacuolar H(+)-ATPase intracellularly and on their plasma membranes
34. 2+
35. Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro
36. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro
37. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone
38. Osteoprotegerin and rank ligand expression in prostate cancer
39. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer
40. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice
41. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis
42. Immunohistochemical analysis of type IV collagenase expression in prostatic hyperplasia and adenocarcinoma
43. Immunocytochemical detection of matrix metalloproteinase expression in prostate cancer
44. Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells
45. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia
46. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate
47. Location of 72-kd metalloproteinase (type IV collagenase) in untreated prostatic adenocarcinoma
48. Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia
49. Expression of metalloproteinase genes in human prostate cancer
50. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion
51. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells
52. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases
53. Expression of the matrix metalloproteinase promatrilysin in coculture of prostate carcinoma cell lines
54. Interleukin-6 and prostate cancer progression
55. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice
56. Matrix metalloproteinases, bone matrix turnover and tumor cell proliferation in prostate cancer bone metastasis
57. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice
58. The physiology of parathyroid hormone-related protein
59. Parathyroid hormone-related protein: A potential autocrine growth regulator in human prostate cancer cell lines
60. Prostate carcinoma: Production of bioactive factors
61. Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer
62. Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia
63. Immunohistochemical localization of parathyroid hormone-related protein in prostatic intraepithelial neoplasia
64. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma
65. Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer
66. Ras Activation of human prostate epithelial cells induces overexpression of parathyroid hormone-related peptide
67. Parathyroid hormone related peptide can function as an autocrine growth factor in human renal cell carcinoma
68. The parathyroid hormone-related protein (PTHrP) gene: Use of downstream TATA promotor and PTHrP 1-139 coding pathways in primary breast cancers vary with the occurrence of bone metastasis
69. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
70. Parathyroid hormone-related protein is not an autocrine growth factor for normal prostatic epithelial cells
71. Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death
72. The nucleolar targeting signal (NTS) of parathyroid hormone related protein mediates endocytosis and nucleolar translocation
73. Overexpression of parathyroid hormone-related protein enhances apoptosis in the rat intestinal cell line, IEC-6
74. Opposing mitogenic and anti-mitogenic actions of parathyroid hormone-related protein in vascular smooth muscle cells: A critical role for nuclear targeting
75. Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone-related protein
76. Prostatespecific antigen cleaves parathyroid hormonerelated protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts
77. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo
78. Interleukin-6-type cytokines
79. The biology of interleukin-6
80. Interleukin-6 receptor and signals
81. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site
82. Soluble receptors for cytokines and growth factors: Generation and biological function
83. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor
84. Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acutephase proteins
85. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma
86. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer
87. Interleukin-6: A candidate mediator of human prostate cancer morbidity
88. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer
89. Development of an animal model for prostate cancer cell metastasis to adult human bone
90. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia
91. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue
92. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty
93. The role of IL-6 type cytokines and their receptors in bone
94. Estrogen loss upregulates hematopoiesis in the mouse: A mediating role of IL-6
95. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion
96. The role of osteoblast density and endogenous interleukin-6 production in osteoclast formation from the hemopoietic stem cell line FDCP-MIX C2GM in coculture with primary osteoblasts
97. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines
98. Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells
99. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption
100. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo
101. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice
102. Oral bisphosphonates: A review of clinical use in patients with bone metastases
103. Bisphosphonates as anticancer drugs
104. Bisphosphonates and the prevention of metastasis
105. Relationship between bisphosphonate concentration and osteoclast activity and viability
106. Mechanisms of action of the bisphosphonates
107. Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice
108. Treatment with ibandronate preserves bone in experimental tumour-induced bone loss
109. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma
110. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system
111. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2
112. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
113. Bisphosphonates and breast carcinoma: Present and future
114. Bisphosphonates in multiple myeloma
115. Antitumour activity of bisphosphonates in human myeloma cells
116. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway
117. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells
118. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
119. The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma
120. Additive antitumor activities of taxolds in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone
121. Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells
122. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton
123. The role of bisphosphonates in the treatment of bone metastases - The U.S. experience
124. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer
125. Skeletal response to clodronate in prostate cancer with bone metastases
126. Preliminary evidence that oral clodronate delays symptomatic progression of bone metastases from prostate cancer: First results of the MRC Pr05 trial
127. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM)
128. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
129. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials